Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
An announcement from ANGLE plc ( (GB:AGL) ) is now available.
ANGLE plc announced the presentation of independent findings by Weill Cornell Medicine at the San Antonio Breast Cancer Symposium, supporting ANGLE’s HER2 assay development program. The Parsortix-based HER2 workflow could revolutionize patient stratification for treatment with HER2 antibody drug conjugates (ADCs) by providing a semi-automated, quantitative assessment of HER2 status in circulating tumor cells (CTCs). This is particularly impactful as HER2 status often changes over time, and the new method could allow for real-time assessment, enabling better-targeted treatments and potentially expanding the eligibility for ADC therapies to patients previously classified as HER2-negative.
More about ANGLE plc
ANGLE plc is a leading company in the liquid biopsy industry, specializing in innovative circulating tumor cell (CTC) solutions applicable in research, drug development, and clinical oncology. Their flagship technology, the Parsortix® PC1 System, is FDA cleared and used for comprehensive analysis of blood samples to aid in diagnostics and personalized medicine.
YTD Price Performance: -4.09%
Average Trading Volume: 1,295,286
Technical Sentiment Consensus Rating: Buy
Current Market Cap: £36.28M
For an in-depth examination of AGL stock, go to TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Broadcom Stock
- ‘Get in for 2025 Gains,’ Says Cowen on Amazon Stock
- Top Analyst Sets the Stage for Nike Stock Ahead of Earnings
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
